Journal
CELLS
Volume 12, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cells12121609
Keywords
alloreactive; graft rejection; PD-L1; graft versus host disease (GVHD); autoimmunity
Categories
Ask authors/readers for more resources
Over the past decade, PD-L1 has become a prominent target in cancer immunotherapies, but its potential as an immunosuppressive therapy has been limited. This review presents the immunological basis of graft rejection and GVHD, and summarizes the molecular interactions of PD-L1 and PD-1. It also provides a translational perspective on how manipulating PD-L1 can increase immune tolerance and improve graft survival.
Over the past decade, Programmed Death-Ligand 1 (PD-L1) has emerged as a prominent target for cancer immunotherapies. However, its potential as an immunosuppressive therapy has been limited. In this review, we present the immunological basis of graft rejection and graft-versus-host disease (GVHD), followed by a summary of biologically relevant molecular interactions of both PD-L1 and Programmed Cell Death Protein 1 (PD-1). Finally, we present a translational perspective on how PD-L1 can interrupt alloreactive-driven processes to increase immune tolerance. Unlike most current therapies that block PD-L1 and/or its interaction with PD-1, this review focuses on how upregulation or reversed sequestration of this ligand may reduce autoimmunity, ameliorate GVHD, and enhance graft survival following organ transplant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available